HU229043B1 - Eljárás obesitas-ellenes és antidiabetikus tulajdonságokkal rendelkezõ (aril-etanol)-amin-származékok elõállítására - Google Patents

Eljárás obesitas-ellenes és antidiabetikus tulajdonságokkal rendelkezõ (aril-etanol)-amin-származékok elõállítására Download PDF

Info

Publication number
HU229043B1
HU229043B1 HU0203640A HUP0203640A HU229043B1 HU 229043 B1 HU229043 B1 HU 229043B1 HU 0203640 A HU0203640 A HU 0203640A HU P0203640 A HUP0203640 A HU P0203640A HU 229043 B1 HU229043 B1 HU 229043B1
Authority
HU
Hungary
Prior art keywords
alkyl
hydrogen
amino
formula
hydroxy
Prior art date
Application number
HU0203640A
Other languages
English (en)
Hungarian (hu)
Inventor
Ronnie Maxwell Lawrence
Alan Millar
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HUP0203640A2 publication Critical patent/HUP0203640A2/hu
Publication of HUP0203640A3 publication Critical patent/HUP0203640A3/hu
Publication of HU229043B1 publication Critical patent/HU229043B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
HU0203640A 1999-12-11 2000-12-08 Eljárás obesitas-ellenes és antidiabetikus tulajdonságokkal rendelkezõ (aril-etanol)-amin-származékok elõállítására HU229043B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9929297.1A GB9929297D0 (en) 1999-12-11 1999-12-11 Process
PCT/GB2000/004697 WO2001042195A1 (en) 1999-12-11 2000-12-08 Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties

Publications (3)

Publication Number Publication Date
HUP0203640A2 HUP0203640A2 (hu) 2003-02-28
HUP0203640A3 HUP0203640A3 (en) 2003-08-28
HU229043B1 true HU229043B1 (hu) 2013-07-29

Family

ID=10866125

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203640A HU229043B1 (hu) 1999-12-11 2000-12-08 Eljárás obesitas-ellenes és antidiabetikus tulajdonságokkal rendelkezõ (aril-etanol)-amin-származékok elõállítására

Country Status (23)

Country Link
US (1) US6548523B2 (enExample)
EP (1) EP1235788B1 (enExample)
JP (1) JP4903964B2 (enExample)
KR (1) KR100683614B1 (enExample)
CN (1) CN1224609C (enExample)
AT (1) ATE292110T1 (enExample)
AU (1) AU769387B2 (enExample)
BR (1) BRPI0016187B1 (enExample)
CA (1) CA2394117C (enExample)
CZ (1) CZ303143B6 (enExample)
DE (1) DE60019157T2 (enExample)
ES (1) ES2236020T3 (enExample)
GB (1) GB9929297D0 (enExample)
HK (1) HK1045988B (enExample)
HU (1) HU229043B1 (enExample)
IL (1) IL149585A0 (enExample)
NO (1) NO323239B1 (enExample)
NZ (1) NZ518795A (enExample)
PL (1) PL200540B1 (enExample)
PT (1) PT1235788E (enExample)
TR (1) TR200201528T2 (enExample)
WO (1) WO2001042195A1 (enExample)
ZA (1) ZA200204585B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230147A1 (de) * 2001-10-09 2004-01-15 Profos Ag Verfahren zur unspezifischen Anreicherung von Bakterienzellen
US7158049B2 (en) * 2003-03-24 2007-01-02 Schlumberger Technology Corporation Wireless communication circuit
US8213085B2 (en) * 2008-01-18 2012-07-03 Visera Technologies Company Limited Image sensor device with high photosensitivity
US8778998B2 (en) * 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US8642661B2 (en) 2010-08-03 2014-02-04 Altherx, Inc. Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
SG11201404776PA (en) 2012-02-09 2014-09-26 Altherx Inc Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1551260A (en) 1976-02-09 1979-08-30 Allen & Hanburys Ltd Phenylethanolamine derivatives
JP2577222B2 (ja) * 1987-04-10 1997-01-29 興和株式会社 新規な置換アニリド誘導体
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
GB9525121D0 (en) 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
BR9910092A (pt) * 1998-05-01 2002-01-22 Abbott Lab Inibidores de beta-aminoácido substituìdo de metionina aminopeptidase-2
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US20020198220A1 (en) 2002-12-26
KR100683614B1 (ko) 2007-02-16
DE60019157T2 (de) 2006-02-02
ZA200204585B (en) 2003-12-31
CA2394117C (en) 2011-10-04
AU2191101A (en) 2001-06-18
HK1045988A1 (en) 2002-12-20
PL200540B1 (pl) 2009-01-30
PT1235788E (pt) 2005-08-31
NO20022758L (no) 2002-07-01
CZ20022017A3 (cs) 2003-01-15
GB9929297D0 (en) 2000-02-02
EP1235788B1 (en) 2005-03-30
JP4903964B2 (ja) 2012-03-28
WO2001042195A1 (en) 2001-06-14
DE60019157D1 (de) 2005-05-04
CZ303143B6 (cs) 2012-05-02
ATE292110T1 (de) 2005-04-15
HK1045988B (en) 2005-07-15
CA2394117A1 (en) 2001-06-14
TR200201528T2 (tr) 2002-09-23
CN1409700A (zh) 2003-04-09
BR0016187A (pt) 2002-08-13
US6548523B2 (en) 2003-04-15
PL356483A1 (en) 2004-06-28
AU769387B2 (en) 2004-01-22
ES2236020T3 (es) 2005-07-16
IL149585A0 (en) 2002-11-10
CN1224609C (zh) 2005-10-26
HUP0203640A3 (en) 2003-08-28
NO323239B1 (no) 2007-02-05
NZ518795A (en) 2004-02-27
BRPI0016187B1 (pt) 2016-08-02
HUP0203640A2 (hu) 2003-02-28
KR20020061636A (ko) 2002-07-24
NO20022758D0 (no) 2002-06-10
JP2003516383A (ja) 2003-05-13
EP1235788A1 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
EP2341044B1 (en) Cycloalkylamine derivative
HU229043B1 (hu) Eljárás obesitas-ellenes és antidiabetikus tulajdonságokkal rendelkezõ (aril-etanol)-amin-származékok elõállítására
CA2775229C (en) Process for the preparation of sorafenib tosylate
JP4137053B2 (ja) 新規形態のｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニン
JP2009502975A (ja) ５−置換テトラゾールの単離方法本発明は、相当するニトリルから出発して閉環を有機溶媒中でアルカリ、アルカリ土類金属または有機錫のアジ化物を用いて起こさせることで生じさせた一般式ｉ：
CN116655605B (zh) 一种苯基吡唑类化合物、及其制备方法和应用
CN102781907B (zh) 甲状腺激素及其盐的制备方法
CN105461662A (zh) 一种抗hiv药物中间体的手性环氧化合物的合成方法
WO2018127783A1 (ja) イオン液体製造方法
EP2167477A2 (en) Improved process for preparing pure valsartan
CN113387800A (zh) 一种3,5-二甲氧基苯甲酸甲酯的制备方法
JP5318330B2 (ja) Ｎ−アルコキシカルボニルアミノ酸結晶の製造方法
CN114907241B (zh) 一种含氟磺酰基的胍类化合物及其制备方法和应用
JP2009221122A (ja) 蛍光誘導体の製造方法
EP1963309B1 (en) Method for producing metal salts of losartan
JP3089996B2 (ja) 光学活性ピペラジン誘導体の製造方法および製造の中間体
CN118146139A (zh) 一种4-氨基-1-甲基哌啶的合成方法
RU2311412C1 (ru) Способ получения 1,3-ди[4-(6-метил-4-пиримидинон-2-тио)метилфенил]адамантана
KR0181212B1 (ko) 비페닐 유도체 및 이의 제조방법
FR2925053A3 (fr) Reactifs de marquage
CN109761857A (zh) N-2-棕榈酰基-n-6-芴甲氧羰基-l-赖氨酸的提纯方法
MXPA02005823A (en) Process for the preparation of arylethanolamine derivatives having an anti obesity and anti diabetic properties
WO2012015019A1 (ja) アミノアルキルチオ硫酸化合物の製造方法
KR20090051855A (ko) 몬테루카스트 사이클로헥실아민 염의 신규한 결정다형 및그의 제조방법
JPH01151540A (ja) ３―または４―ヒドロキシ―４’―ニトロジフェニルエーテルの精製方法

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees